Sanofi News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

19.12.24	Presse release: Jean-Paul Kress to join Sanofi's Board of Directors (GlobeNewswire)
17.12.24	Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease (GlobeNewswire)
17.12.24	Press Release: Availability of the Q4 2024 Aide-mémoire (GlobeNewswire)
13.12.24	Sanofi's Tolebrutinib Gets FDA Breakthrough Therapy Designation For NrSPMS (RTTNews)
13.12.24	Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis (GlobeNewswire)
11.12.24	Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US (GlobeNewswire)
09.12.24	Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients (GlobeNewswire)
08.12.24	Sanofi-Aventis Announces Positive Results For Rilzabrutinib In Phase 3 ITP Study (RTTNews)
07.12.24	Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP (GlobeNewswire)
06.12.24	Press Release: Availability of the revised financial statements for Sanofi excluding Opella (GlobeNewswire)
03.12.24	Sanofi To Invest $1.05 Bln For New Insulin Production Base In China (RTTNews)
20.11.24	Sanofi: Information concerning the total number of voting rights and shares - October 2024 (GlobeNewswire)
15.11.24	Sanofi, Regeneron's Dupixent SBLA Accepted For FDA Review To Treat Chronic Spontaneous Urticaria (RTTNews)
15.11.24	Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria (GlobeNewswire)
14.11.24	Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma (GlobeNewswire)
06.11.24	Regeneron: EC Approves Dupixent For Young Children With EoE (RTTNews)
06.11.24	Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis (GlobeNewswire)
29.10.24	Sanofi Launches Beyfortus Immunization Against RSV For Infants In Canada This Fall (RTTNews)
25.10.24	Sanofi Q3 Profit Rises - Quick Facts (RTTNews)
25.10.24	Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance (GlobeNewswire)
24.10.24	Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI (GlobeNewswire)
21.10.24	Sanofi Enters Exclusive Negotiations To Sell 50% Stake In Opella To CD&R (RTTNews)
21.10.24	Press Release: Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare (GlobeNewswire)
17.10.24	PAI Partners Raises Offer For Sanofi's Consumer Health Biz Opella: Reports (RTTNews)
17.10.24	Press Release: Sanofi and Orano join forces to develop next-generation radioligand medicines (GlobeNewswire)
17.10.24	Press Release: Sanofi and Orano join forces to develop next-generation radioligand medicines (GlobeNewswire)
16.10.24	FDA Updates Sanofi's FLUBLOK Vaccine Label With New Safety Data For Pregnant Individuals (RTTNews)
15.10.24	Sanofi: Information concerning the total number of voting rights and shares - September 2024 (GlobeNewswire)
11.10.24	Press Release: Sanofi in discussions to sell a controlling stake in Opella (GlobeNewswire)
09.10.24	Sanofi : Beyfortus Data Reinforce Effectiveness Against RSV Disease & Hospitalization In Infants (RTTNews)
09.10.24	Press Release: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants (GlobeNewswire)
27.09.24	Regeneron, Sanofi's Dupixent Get FDA Approval For Chronic Obstructive Pulmonary Disease Treatment (RTTNews)
27.09.24	Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD (GlobeNewswire)
27.09.24	Regeneron, Sanofi Say Dupixent Approved In China To Treat Chronic Obstructive Pulmonary Disease (RTTNews)
27.09.24	Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD (GlobeNewswire)
26.09.24	Press Release: Availability of the Q3 2024 Aide mémoire (GlobeNewswire)
21.09.24	Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for trans (GlobeNewswire)
20.09.24	Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old (GlobeNewswire)
20.09.24	Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old (EN, Sanofi-Aventis)
20.09.24	Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study (GlobeNewswire)
20.09.24	Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study (EN, Sanofi-Aventis)
16.09.24	Sanofi: Information concerning the total number of voting rights and shares - August 2024 (GlobeNewswire)
16.09.24	Sanofi To Offer BEYFORTUS Doses To Protect Babies During RSV Season - Quick Facts (RTTNews)
12.09.24	Sanofi, RadioMedix, Orano Med Sign Deal For Next-Gen Radioligand Medicine For Rare Cancers (RTTNews)
12.09.24	Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers (EN, Sanofi-Aventis)
12.09.24	Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers (GlobeNewswire)
11.09.24	Sanofi, Regeneron: ADEPT Study Of Dupixent In Bullous Pemphigoid Meets Endpoints (RTTNews)
11.09.24	Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU (EN, Sanofi-Aventis)
11.09.24	Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU (GlobeNewswire)
11.09.24	Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Roche Hldg G	247.30	0.24 %	K V
Sonova Hldg	292.20	-0.20 %	K V
Swisscom	498.20	-0.66 %	K V
Givaudan	3’881.00	-0.67 %	K V
Kuehne+Nagel Int	200.90	-0.69 %	K V
Lonza Grp	519.00	-1.74 %	K V
Holcim	85.30	-1.93 %	K V
Part Grp Hldg	1’192.00	-2.05 %	K V
UBS Group	26.28	-2.27 %	K V
Sika	213.60	-2.29 %	K V

mehr

12:26		XETRA-Handel TecDAX sackt am Freitagmittag ab
12:26		Euro STOXX 50-Handel aktuell: Euro STOXX 50 am Mittag schwächer
12:26		Börse Frankfurt: DAX fällt am Freitagmittag
12:26		Börse Frankfurt in Rot: LUS-DAX verbucht am Mittag Verluste
12:26		LSE-Handel FTSE 100 am Freitagmittag in Rot
12:26		Anleger in Zürich halten sich zurück: SMI am Freitagmittag in Rot
12:26		SIX-Handel SPI verbucht am Freitagmittag Verluste
11:16		GSK-Aktie verliert: GSK erreicht Fortschritte bei Eierstockkrebs-Therapie